RESUMEN:
Objetivo: Comparar la eficacia, supervivencia y efectos adversos entre cTACE y DEB-TACE en pacientes con carcinoma hepatocelular no candidatos a terapia curativa. Materiales y Métodos: Estudio retrospectivo de pacientes con carcinoma hepatocelular sometidos a cTACE o DEB-TACE para tratamiento paliativo entre enero de 2009 y diciembre de 2021. Se utilizó el método de Kaplan-Meier para el análisis de supervivencia. Un valor de p < 0,05 se consideró estadísticamente significativo. Resultados: Se evaluaron 268 pacientes, de los cuales 70 fueron sometidos a DEB-TACE y 198 a cTACE. No hubo diferencia en cuanto al sexo, edad y etiología de la cirrosis. El grupo cTACE presentó un mayor porcentaje de respuesta completa en exámenes de imagen (31,8% vs. 16,1%) y el grupo DEB-TACE presentó un mayor porcentaje de respuesta parcial (33,9% vs. 19,7%), con un valor de p = 0,014. La mortalidad fue similar. Las tasas de supervivencia para los grupos DEB-TACE y cTACE fueron 87,0% y 87,9% a un año, 35,1% y 32,9% a tres años y 20,5% y 18,1% a cinco años, respectivamente (p = 0,661). En relación a la frecuencia de eventos adversos, no hubo diferencia significativa entre los grupos (7,1% en DEB-TACE vs. 17,8% en cTACE; p = 0,052). La complicación más común, en ambos grupos, fue el síndrome post-embolia. Conclusión: Aunque se observó una mayor frecuencia de respuesta completa en pacientes sometidos a cTACE, no hubo diferencia en la supervivencia de los pacientes entre los grupos. La tasa de eventos adversos también fue similar.

ABSTRACT:
Objective: To compare conventional transarterial chemoembolization (cTACE) and drug-eluting bead TACE (DEB-TACE) in terms of efficacy, survival, and adverse effects in patients with hepatocellular carcinoma who are not candidates for curative therapy. Materials and Methods: This was a retrospective study of patients with hepatocellular carcinoma who underwent cTACE or DEBTACE for palliative treatment between January 2009 and December 2021. The Kaplan-Meier method was used for survival analysis. Values of p < 0.05 were considered statistically significant. Results: We evaluated 268 patients, of whom 70 underwent DEB-TACE and 198 underwent cTACE. There was no significant difference between the groups regarding sex, age, or etiology of cirrhosis. The proportion of patients achieving a complete response on imaging examinations was higher in the cTACE group (31.8% vs. 16.1%), whereas that of patients achieving a partial response was higher in the DEB-TACE group (33.9% vs.19.7%), and the differences were significant (p = 0.014). The mortality rate was similar between the groups. The survival rate in the DEB-TACE and cTACE groups, respectively, was 87.0% and 87.9% at one year, 35.1% and 32.9% at three years, and 20.5% and 18.1% at five years (p = 0.661). There was no significant difference between the DEB-TACE and cTACE groups in terms of the frequency of adverse events (7.1% vs. 17.8%; p = 0.052). The most common complication in both groups was post-embolization syndrome. Conclusion: Although a complete response was more common among the patients who underwent cTACE, there was no difference in survival between the groups and the frequency of adverse events was similar.

ABSTRACT:
Objective: To compare conventional transarterial chemoembolization (cTACE) and drug-eluting bead TACE (DEB-TACE) in terms of efficacy, survival, and adverse effects in patients with hepatocellular carcinoma who are not candidates for curative therapy. Materials and Methods: This was a retrospective study of patients with hepatocellular carcinoma who underwent cTACE or DEBTACE for palliative treatment between January 2009 and December 2021. The Kaplan-Meier method was used for survival analysis. Values of p < 0.05 were considered statistically significant. Results: We evaluated 268 patients, of whom 70 underwent DEB-TACE and 198 underwent cTACE. There was no significant difference between the groups regarding sex, age, or etiology of cirrhosis. The proportion of patients achieving a complete response on imaging examinations was higher in the cTACE group (31.8% vs. 16.1%), whereas that of patients achieving a partial response was higher in the DEB-TACE group (33.9% vs.19.7%), and the differences were significant (p = 0.014). The mortality rate was similar between the groups. The survival rate in the DEB-TACE and cTACE groups, respectively, was 87.0% and 87.9% at one year, 35.1% and 32.9% at three years, and 20.5% and 18.1% at five years (p = 0.661). There was no significant difference between the DEB-TACE and cTACE groups in terms of the frequency of adverse events (7.1% vs. 17.8%; p = 0.052). The most common complication in both groups was post-embolization syndrome. Conclusion: Although a complete response was more common among the patients who underwent cTACE, there was no difference in survival between the groups and the frequency of adverse events was similar.